Source comparison
Thymosin Alpha-1 Safety Studies: Clinical vs Observational Comparison
Phase III RCTs (hepatitis B/C) 3,200+ patients 8–12% (vs 8–10% placebo) 0.8% (vs 0.9% placebo) None documented <0.5% Phase III RCTs (melanoma adjuvant) 1,028 patients 9.1% (vs 8.4% control) 4.1% (vs 3.9% control) None attributed to Tα1 0% Post-marketing survei
This comparison does not assign a generated winner or score.
- Phase III RCTs (hepatitis B/C)
- 3,200+ patients
- 8–12% (vs 8–10% placebo)
- 0.8% (vs 0.9% placebo)
- None documented
- <0.5%
- Phase III RCTs (melanoma adjuvant)
- 1,028 patients
- 9.1% (vs 8.4% control)
- 4.1% (vs 3.9% control)
- None attributed to Tα1
- 0%
- Post-marketing surveillance (China)
- 1.8M+ exposures
- 0.031%
- 0.002%
- None reported
- Not tracked
- Combination therapy (Tα1 + interferon)
- 1,214 patients (meta-analysis)
- 42% (interferon baseline ~45%)
- 6.2% (vs 7.8% interferon alone)
- Hepatotoxicity reduced vs interferon monotherapy
- 14% (vs 22% interferon alone)
- Long-term administration (>12 months)
- 680 patients (pooled data)
- 11.3%
- 1.1%
- 0.7%
- Professional Assessment
- Thymosin alpha-1 demonstrates adverse event rates statistically indistinguishable from placebo in controlled trials and sub-1% serious events in real-world use across nearly 2 million exposures. No evidence of cumulative toxicity, organ damage, or dose-limiting side effects exists in any published dataset. This safety profile positions Tα1 as one of the best-tolerated immunomodulators in clinical use.